1. Home
  2. GXAI vs NXL Comparison

GXAI vs NXL Comparison

Compare GXAI & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gaxos.ai Inc.

GXAI

Gaxos.ai Inc.

BUY

Current Price

$0.43

Market Cap

8.6M

Sector

N/A

ML Signal

BUY

Logo Nexalin Technology Inc.

NXL

Nexalin Technology Inc.

HOLD

Current Price

$2.45

Market Cap

7.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GXAI
NXL
Founded
2021
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.6M
7.5M
IPO Year
2022
2022

Fundamental Metrics

Financial Performance
Metric
GXAI
NXL
Price
$0.43
$2.45
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
165.0K
★ 2.0M
Earning Date
11-12-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 71.35
39.76
EPS
★ N/A
N/A
Revenue
★ $1,933,030.00
$301,647.00
Revenue This Year
$462.16
$14.37
Revenue Next Year
$30.00
$100.00
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 47901.74
78.78
52 Week Low
$0.42
$0.22
52 Week High
$5.26
$101.40

Technical Indicators

Market Signals
Indicator
GXAI
NXL
Relative Strength Index (RSI) 26.01 32.63
Support Level $0.42 $0.22
Resistance Level $2.58 $5.36
Average True Range (ATR) 0.03 0.84
MACD 0.01 -0.02
Stochastic Oscillator 1.65 2.36

Price Performance

Historical Comparison
GXAI
NXL

About GXAI Gaxos.ai Inc.

Gaxos.AI Inc is a technology company focused on reshaping the way people interact with artificial intelligence across everyday life and high-impact industries. It is engaged in building a portfolio of AI-powered solutions designed to make advanced technology more practical, accessible, and transformative. The company's portfolio spans defense, health and wellness, entertainment, and productivity - bringing intelligent tools to markets where innovation can drive meaningful real-world outcomes. It operates as a single operating segment technology-based company that is developing applications aimed at redefining the way it utilizes artificial intelligence (AI) to optimize the user experience.

About NXL Nexalin Technology Inc.

Nexalin Technology Inc designs and develops neurostimulation products and bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The Company has developed the Generation 1 (Gen 1) medical device, a cranial electrotherapy stimulation (CES) device classified by the U.S. Food and Drug Administration (FDA) as a Class II device. The Company operates as a single operating and reportable segment, focused on the design and development of innovative neurostimulation products. The Company focuses on treating mental health conditions without reliance on drugs or psychotherapy. Geographically, it generates sales in the USA and China, with China generating the maximum sales.

Share on Social Networks: